
FDA Endorses Donanemab, Revolutionary Alzheimer’s Treatment
The unanimous 11-0 FDA vote clears an exciting path for this new Alzheimer’s drug.
The unanimous 11-0 FDA vote clears an exciting path for this new Alzheimer’s drug.
Galantamine treats Alzheimer’s. Artificial intelligence and biosensors may pave the way to make this drug faster and cheaper.
Trontinemab is a very exciting experimental drug, showing great promise in rapidly clearing Alzheimer’s amyloid plaques from the brains of affected individuals, with remarkably little side effects.
See why Cognito’s headset received FDA Breakthrough Device Designation for addressing cognitive and functional symptoms associated with Alzheimer’s.
Walk through the various steps that occur as a person participates in the Alzheimer’s Disease Neuroimaging Initiative (ADNI) project.
“It is exciting to see efficacy of potential new drugs for Dementia with Lewy Bodies, the most common dementia after Alzheimer’s. It is a huge area of unmet need,” said Dr. Marwan Sabbagh.
Now, a third new Alzheimer’s drug expected to be approved by the Food and Drug Administration (FDA),. The field of new drugs is beginning to show progress in the fight to slow the disease.
Doctors routinely diagnose and track dementia. “Neuropsychological tests” are non-invasive, using interviews or paper/pen tests. More invasive diagnostics include powerful MRI and PET scans.
The new Alzheimer’s injections Aduhelm and Lecanemab offer hope. Now, Mastinimab is trying to break through to the next level with a simpler pill. Mastinimab fights Alzheimer’s via a revolutionary mechanism of action. Learn why the FDA approved Mastinimab’s final round of trials.
CLINICAL TRIALS VIDEO: Thin electrical wires were surgically implanted in the brain of Alzheimer’s patients. Called “Deep Brain Stimulation”, see how this brain “pacemaker” improves
The Housing Learning and Improvement Network looks at the design process and philosophy behind creating a successful Extra Care scheme.
Get your message out with Alzheimer’s Weekly! Publish your news prominently on AlzheimersWeekly.com and email it to 30,000 opt-in subscribers. The fee is just $100.
Explore lithium’s impact on Alzheimer’s and dementia prevention. See practical takeaways, including what Dr. Norwitz is doing himself to protect his family’s cognitive health.
SHORT-TERM MEMORY lapses are obvious signs of Alzheimer’s, but other tell-tale signals begin to show much earlier. Learn how to look for semantic impairments, such as simple questions about size.
Three important dementia studies focus on HS-AGING, a type of dementia almost as common as Alzheimer’s in the 85+ group. Yet few people have heard of it. Why? What makes it different?
An intriguing study of 120 grandmothers might surprise you. Doctors know socially engaged people have better cognition and less dementia. But can a person get too much of a good thing? What’s the right balance?
Enjoy this great duet between a musician with dementia and his son. A triumph of spirit over Alzheimer’s! Sing-a-long if you like!
No spam, only news and updates.